论文部分内容阅读
目的探讨血清甲胎蛋白(AFP)、α-L岩藻糖苷酶(AFU)、糖类抗原(CA19-9)联合检测在原发性肝癌(PHC)中的诊断价值。方法 2011年6月~2012年6月住院的原发性肝癌(PHC)患者34例,另选32例肝硬化患者及同期在医院内体检的健康者39例作对照,检测3组的血清AFP、AFU、CA19-9水平,并对其进行比较。结果原发性肝癌(PHC)组AFP、AFU、CA19-9水平明显高于肝硬化组和健康组;原发性肝癌(PHC)组的联合检测阳性率为91.2%,明显高于肝硬化组的43.8%及健康组的2.6%,差异有统计学意义(P<0.05)。结论患者血清AFP、AFU、CA19-9的联合检测可提高PHC诊断率,对早期原发性肝癌诊断、治疗具有重要的临床意义。
Objective To investigate the diagnostic value of combined detection of serum alpha-fetoprotein (AFP), α-L fucosidase (AFU) and carbohydrate antigen (CA19-9) in primary hepatocellular carcinoma (PHC). Methods Thirty-four patients with primary liver cancer (PHC) who were hospitalized from June 2011 to June 2012 were enrolled in this study. Thirty-two patients with cirrhosis and 39 healthy controls were enrolled in this study. Serum AFP , AFU, CA19-9 levels, and compare them. Results The positive rates of AFP, AFU and CA19-9 in primary hepatocellular carcinoma (PHC) group were significantly higher than those in cirrhosis and healthy subjects. The positive rate of combined detection in primary hepatocellular carcinoma (PHC) group was 91.2%, significantly higher than that in cirrhosis group Of 43.8% and 2.6% of healthy group, the difference was statistically significant (P <0.05). Conclusions The combined detection of serum AFP, AFU and CA19-9 can improve the diagnosis rate of PHC and has important clinical significance in the diagnosis and treatment of early-stage primary liver cancer.